Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.93 |
| ▸ | CA6 | P23280 | 5/20 | 0.93 |
| ▸ | CA7 | P43166 | 5/20 | 0.93 |
| ▸ | CA9 | Q16790 | 5/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.93 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.93 |
| ▸ | CA2 | P00918 | 4/20 | 0.93 |
| ▸ | CA4 | P22748 | 4/20 | 0.93 |
| ▸ | CA5A | P35218 | 4/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.93 |
| ▸ | F13A1 | P00488 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | THPO | P40225 | 2/20 | 0.93 |
| ▸ | CASP2 | P42575 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 2/20 | 0.93 |
| ▸ | RECQL | P46063 | 2/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | CA3 | P07451 | 3/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360676 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL4288395 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3159000 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3165616 | 0.97 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL31129279 | 0.97 | CA12 (0.87) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3158875 | 0.97 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3169101 | 0.97 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL333029 | 0.97 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL868754 | 0.96 | CA12 (0.86) | CA12CA6CA7CA9CA14 | |
| Thermine SCHEMBL181589 | 0.96 | CA12 (0.86) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125031-B1 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | MARINA BIOTECH INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2125029-B1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8193246-B2 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193246-B2 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | MDRNA RESEARCH, INC. | 2010-01-28 | — | — | US | disclosed |
| EP-2125031-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2125029-A2 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| WO-2008074488-A2 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074487-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | CA12 1469/4885CA6 454/4885CA7 512/4885 |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | SREBF1, SREBF2, ELOVL1 | CA12 2211/4885CA6 1409/4885CA7 1360/4885 |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | CA12 1469/4885CA6 454/4885CA7 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.